Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision-making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ
Μορφή: Journal article
Γλώσσα:English
Έκδοση: Wiley 2016

Παρόμοια τεκμήρια